Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haruko Takizawa

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
The American Journal of Hospice & Palliative Care|November 22, 2022
Factors Associated With Survival in Patients With End-of-Life Hematological Malignancies Who Received Chemotherapy: A Retrospective Single-Institution StudyHiroko Iizuka-Honma, Toru Mitsumori, Seiichiro Yoshikawa, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|March 29, 2023
Development of rapidly fatal TAFRO syndrome-like features in a patient with essential thrombocythemiaHiroko Iizuka-Honma, Haruko Takizawa, Hideaki Nitta, et al.
JCO Oncology Practice|August 6, 2021
Prognostic Value of Palliative Prognostic Index for Hospitalized Patients With End-of-Life Hematologic Malignancies in a Japanese University HospitalHiroko Iizuka-Honma, Toru Mitsumori, Seiichiro Yoshikawa, et al.
Internal Medicine (Tokyo, Japan)|July 6, 2022
Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to TirabrutinibHiroko Iizuka-Honma, Haruko Takizawa, Toru Mitsumori, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2021
The Current Status of Screening for Essential Thrombocythemia and Polycythemia Vera in Clinical Practice-Report from a Single InstitutionYasunobu Sekiguchi, Misa Nishitani, Haruko Takizawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 16, 2021
Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical InstitutionYasunobu Sekiguchi, Hiroko Iizuka, Haruko Takizawa, et al.
International Journal of Hematology|March 30, 2017
Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD)Yasunobu Sekiguchi, Haruko Takizawa, Tadaaki Inano, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 19, 2021
Low‒Risk Essential Thrombocythemia Who Presented with Recurrent Episodes of Cerebral Hemorrhage during Pregnancy and Developed Cerebral Infarction during PuerperiumYasunobu Sekiguchi, Misa Nishitani, Haruko Takizawa, et al.
Journal of Clinical Medicine|October 14, 2023
Possible New Histological Prognostic Index for Large B-Cell LymphomaHideaki Nitta, Haruko Takizawa, Toru Mitsumori, et al.
Journal of Clinical Medicine|January 28, 2026
A New Histology-Based Prognostic Index for Acute Lymphoblastic Leukemia: Preliminary Results of the "ALL Urayasu Classification"Toru Mitsumori, Hideaki Nitta, Haruko Takizawa, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
The American Journal of Hospice & Palliative Care|November 22, 2022
Factors Associated With Survival in Patients With End-of-Life Hematological Malignancies Who Received Chemotherapy: A Retrospective Single-Institution StudyHiroko Iizuka-Honma, Toru Mitsumori, Seiichiro Yoshikawa, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|March 29, 2023
Development of rapidly fatal TAFRO syndrome-like features in a patient with essential thrombocythemiaHiroko Iizuka-Honma, Haruko Takizawa, Hideaki Nitta, et al.
JCO Oncology Practice|August 6, 2021
Prognostic Value of Palliative Prognostic Index for Hospitalized Patients With End-of-Life Hematologic Malignancies in a Japanese University HospitalHiroko Iizuka-Honma, Toru Mitsumori, Seiichiro Yoshikawa, et al.
Internal Medicine (Tokyo, Japan)|July 6, 2022
Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to TirabrutinibHiroko Iizuka-Honma, Haruko Takizawa, Toru Mitsumori, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2021
The Current Status of Screening for Essential Thrombocythemia and Polycythemia Vera in Clinical Practice-Report from a Single InstitutionYasunobu Sekiguchi, Misa Nishitani, Haruko Takizawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 16, 2021
Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical InstitutionYasunobu Sekiguchi, Hiroko Iizuka, Haruko Takizawa, et al.
International Journal of Hematology|March 30, 2017
Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD)Yasunobu Sekiguchi, Haruko Takizawa, Tadaaki Inano, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 19, 2021
Low‒Risk Essential Thrombocythemia Who Presented with Recurrent Episodes of Cerebral Hemorrhage during Pregnancy and Developed Cerebral Infarction during PuerperiumYasunobu Sekiguchi, Misa Nishitani, Haruko Takizawa, et al.
Journal of Clinical Medicine|October 14, 2023
Possible New Histological Prognostic Index for Large B-Cell LymphomaHideaki Nitta, Haruko Takizawa, Toru Mitsumori, et al.
Journal of Clinical Medicine|January 28, 2026
A New Histology-Based Prognostic Index for Acute Lymphoblastic Leukemia: Preliminary Results of the "ALL Urayasu Classification"Toru Mitsumori, Hideaki Nitta, Haruko Takizawa, et al.
Pageof 2